G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.64) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.01. View G1 Therapeutics' Earnings History.
What price target have analysts set for GTHX?
8 equities research analysts have issued 1 year price objectives for G1 Therapeutics' shares. Their forecasts range from $41.00 to $80.00. On average, they anticipate G1 Therapeutics' stock price to reach $66.00 in the next twelve months. This suggests a possible upside of 230.7% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (8/8/2018)
- 2. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
Has G1 Therapeutics been receiving favorable news coverage?
Media headlines about GTHX stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. G1 Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Arena Pharmaceuticals (ARNA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Akcea Therapeutics (AKCA), Heron Therapeutics (HRTX), Amicus Therapeutics (FOLD), Portola Pharmaceuticals (PTLA) and Madrigal Pharmaceuticals (MDGL).
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Mr. Barclay A. Phillips, CFO, Sr. VP of Corp. Devel. & Sec. (Age 56)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
- Dr. Jay C. Strum, Chief Scientific Officer (Age 55)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.28%), Bank of New York Mellon Corp (2.92%), Hillhouse Capital Advisors Ltd. (2.55%), BB Biotech AG (1.81%), Northern Trust Corp (0.76%) and Geode Capital Management LLC (0.75%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which major investors are selling G1 Therapeutics stock?
GTHX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Barclays PLC, MetLife Investment Advisors LLC, United Services Automobile Association, TD Asset Management Inc., New York State Common Retirement Fund, California Public Employees Retirement System and Virtus ETF Advisers LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Barclay A Phillips, Clay Thorp, Jay Strum, Jennifer K Moses, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Insider Buying and Selling for G1 Therapeutics.
Which major investors are buying G1 Therapeutics stock?
GTHX stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., BB Biotech AG, Rhenman & Partners Asset Management AB, BlackRock Inc., Dimensional Fund Advisors LP, Citigroup Inc., Two Sigma Investments LP and SG Americas Securities LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, John Demaree and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $19.96.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $742.31 million. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
